within Pharmacolibrary.Drugs.ATC.A;

model A07AA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.075,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Vancomycin is a glycopeptide antibiotic that is used for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. It is especially used when other antibiotics are ineffective or contraindicated. Vancomycin is approved by major regulatory agencies and is widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters for adult patients with normal renal function receiving intravenous vancomycin therapy.</p><h4>References</h4><ol><li>Onyinye Onyeka Akunne, Pierre Mugabo, Andrew C Argent,Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review.,European journal of drug metabolism and pharmacokinetics,2022<a href='https://pubmed.ncbi.nlm.nih.gov/34750740/'>https://pubmed.ncbi.nlm.nih.gov/34750740/</a></li><li>R C Moellering,Pharmacokinetics of vancomycin.,The Journal of antimicrobial chemotherapy,1984<a href='https://pubmed.ncbi.nlm.nih.gov/6394577/'>https://pubmed.ncbi.nlm.nih.gov/6394577/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07AA09;
